Related Experiment Video
Updated: May 25, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
Published on: July 14, 2021
Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy
Estelle Ayme-Dietrich1, Roland Lawson, Bernard Gasser
1Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université de Strasbourg, 11 rue Humann, 67085 Strasbourg, France.
Abstract:
The authors describe the case of a simultaneous mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy in a 40-year-old woman. Four years before, she underwent a mitral valve replacement after the diagnosis of mitral regurgitation during benfluorex treatment (150 mg/day). This drug was reintroduced postoperatively. She presented with exercise and sometimes resting dyspnoea. The bioprosthesis and aortic valves exhibited similar histopathological lesions. Thickening and plaque deposits made by smooth muscle alpha actin- and vimentin-positive cells in a glycosaminoglycan matrix were observed. The study discusses the putative contribution of circulating progenitor cells activated by 5-HT(2B) receptor agonists in the development of drug-induced heart disease.
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Stenosis III: Medical Management
Mitral Stenosis IV: Nursing Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests